Financial Performance - The company's operating revenue for Q1 2024 was ¥244,924,392.62, a decrease of 9.66% compared to ¥271,112,684.09 in the same period last year[10] - Net profit attributable to shareholders was ¥21,411,400.56, down 42.00% from ¥36,919,134.34 year-on-year[10] - The company reported a basic earnings per share of ¥0.04, a decrease of 50.00% from ¥0.08 in the same period last year[10] - Net profit for the current period was ¥21,411,400.56, down 42.06% from ¥36,919,134.34 in the previous period[39] - The company reported a total comprehensive income of ¥21,411,400.56, down from ¥36,919,134.34 in the previous period[39] Cash Flow - The net cash flow from operating activities was -¥43,921,036.88, a significant decline of 724.68% compared to ¥7,030,970.34 in the previous year[10] - Cash flow from operating activities showed a net outflow of ¥43,921,036.88, contrasting with a net inflow of ¥7,030,970.34 in the previous period[39] - The net cash flow from investing activities was -$208.21 million, a decrease from $295.50 million in the previous period[40] - Total cash inflow from financing activities was $47.51 million, compared to $17.61 million in the prior period[40] - The net cash flow from financing activities improved to $8.65 million from -$83.83 million year-over-year[40] - Cash and cash equivalents at the end of the period decreased to $118.77 million from $775.00 million in the previous period[40] - Cash outflow from investing activities totaled $1.12 billion, significantly higher than $361.97 million last year[40] - Cash inflow from borrowing was $40 million, an increase from $10 million in the previous period[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,521,677,577.49, an increase of 1.02% from ¥2,496,281,841.43 at the end of the previous year[10] - The total liabilities rose to CNY 845,768,707.27 from CNY 746,190,648.20, indicating an increase of approximately 13.3%[27] - The company's total assets reached CNY 2,521,677,577.49, up from CNY 2,496,281,841.43, representing a growth of about 1.0%[27] - The total liabilities and equity amounted to ¥2,521,677,577.49, compared to ¥2,496,281,841.43 in the previous period[29] Research and Development - Research and development expenses increased by 250.79% to ¥7,960,492.47, compared to ¥2,269,315.26 in the same period last year, reflecting a focus on chemical and digital technology[15] - Research and development expenses increased significantly to ¥7,960,492.47 from ¥2,269,315.26, marking a rise of 250.00%[30] Equity and Retained Earnings - The company’s retained earnings decreased to ¥277,861,713.54 from ¥352,450,312.98, a decline of 21.14%[29] - The total equity remained stable at CNY 480,000,000.00[27] Other Financial Metrics - The weighted average return on net assets was 1.22%, down from 2.21% in the same period last year, indicating a decline in profitability[10] - The company received government subsidies amounting to ¥65,151.61, a decrease of 96.82% from ¥2,048,217.00 in the previous year[15] - The company experienced a 1198.63% increase in other payables, amounting to ¥101,367,471.69, primarily due to declared but unpaid dividends of ¥96 million[15] Current Assets and Inventory - The total current assets increased to CNY 2,184,356,528.32 from CNY 2,160,200,755.89, reflecting a growth of approximately 1.1%[24] - Cash and cash equivalents decreased to CNY 333,368,918.30 from CNY 434,261,221.35, a decline of about 23.2%[24] - The accounts receivable increased to CNY 89,858,140.52 from CNY 72,605,819.17, showing a rise of approximately 23.7%[24] - The inventory balance increased to CNY 45,035,001.11 from CNY 43,853,814.46, reflecting a growth of about 2.7%[24] - The company's other receivables increased to CNY 3,521,268.12 from CNY 3,204,672.56, indicating a growth of approximately 9.9%[24] Borrowings - The company's short-term borrowings slightly increased to CNY 604,157,409.67 from CNY 601,584,187.47, a change of about 0.3%[27] Audit Status - The company did not undergo an audit for the first quarter report[41]
华融化学(301256) - 2024 Q1 - 季度财报